Samsung Biologics and Enzolytics have entered a strategic contract development and manufacturing organization (CDMO) collaboration agreement to develop and produce monoclonal antibody treatments for human immunodeficiency virus (HIV) and Covid-19.
AstraZeneca has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AZD7442 to prevent symptomatic Covid-19.
Australia has signed an agreement for 300,000 courses of molnupiravir, an antiviral pill that has shown signs of reducing deaths and hospitalisations due to Covid-19.
Trevena has announced positive results from a proof-of-concept clinical trial during which its new AT1 receptor-selective agonist, TRV027, was found to be well-tolerated in Covid-19 patients who have been hospitalised.
Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years.
The US Food and Drug Administration (FDA) has declined Humanigen’s request for Emergency Use Authorization (EUA) of its antibody lenzilumab to treat newly hospitalised Covid-19 patients.
AIM ImmunoTech has submitted a pre-investigational new drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a study of Ampligen as a potential infusion treatment for post-Covid-19 cognitive dysfunction (PCCD).
The Drugs Controller General of India (DCGI) has given approval to Reliance Life Sciences to conduct a Phase I clinical trial of its Covid-19 vaccine with certain conditions.
Senhwa Biosciences has announced that its oral drug, Silmitasertib, has received positive feedback from an independent Data Monitoring Committee (DMC) in an interim review of Phase II investigator-initiated trial in patients with severe Covid-19.
Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.